This third of five exclusive episodes explores how clinicians can navigate newly approved MASH therapies -- resmetirom (Rezdiffra) and semaglutide (Wegovy) -- and how to tailor treatment choices based ...
The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...
Esperion faces pressure from emerging oral PCSK9i and CETP inhibitors, which offer superior LDL-c lowering. See why I rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback